Serotonin 1 (5-HT1) receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serotonin 1 (5-HT1) receptor as ChEMBL target CHEMBL2095159, mapped to UniProt P28564. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Serotonin 1 (5-HT1) receptor matters
Serotonin 1 (5-HT1) receptor is reviewed as 5-hydroxytryptamine receptor 1B (UniProt P28564); the current evidence base includes 16 approved drugs, 372 compounds, and 63 assays, with lead potency reaching pChEMBL 9.3.
5-hydroxytryptamine receptor 1B Sequence length is 386 aa.
Review this target as Serotonin 1 (5-HT1) receptor, mapped to UniProt P28564. ChEMBL maps the protein component as 5-hydroxytryptamine receptor 1B. Sequence length is 386 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 16 approved drugs, 372 compounds, and 63 assays for this target. The dominant activity type is IC50. CHEMBL300585 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL300585 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Serotonin 1 (5-HT1) receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P28564, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL300585
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL57483
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL294425
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL274728
|
8.9 | IC50 | — |
|
|
No preferred name
CHEMBL57506
|
8.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
GEPIRONE HYDROCHLORIDE
CHEMBL1204187
|
2023 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
BUSPIRONE HYDROCHLORIDE
CHEMBL1200399
|
1986 |
|
|
PINDOLOL
CHEMBL500
|
1982 |
|
|
METHYSERGIDE
CHEMBL1065
|
1962 |
|
|
MIANSERIN
CHEMBL6437
|
— |